Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 423 recruiting now early-phase tilt #1 of 28,707 conditions

Breast Cancer: early-phase trial registry

423 of 1,251 indexed Breast Cancer trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #1 of 28,707 conditions by registered trial count.

1,251 US clinical trials · 423 currently recruiting · #1 of 28,707 conditions by registered trial count

Breast Cancer: 1,251 US clinical trials tracked, 423 recruiting.

Breast Cancer is the subject of 1,251 registered US clinical trials on ClinicalTrials.gov, 423 of them currently open to new participants. 120 are in Phase 3-4 (later-stage) and 491 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 98 of these trials.

Enrollment posture brief

Registry condition breast-cancer

OPEN 423 | RECR 34% | LATE 120 | EARLY 491 | RANK #1 | SPON 98

Nearest open-share peer: Refractory Multiple Myeloma (34% recruiting · 68 trials)

Prostate Cancer36.7%Depression35.7%Breast Cancer (this)34%Obesity28.9%Healthy20.5%
Open-enrollment share among volume-matched conditions near Breast Cancer

Breast Cancer lists 423 open slots (34% of 1,251 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Breast Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Breast Cancer is recruiting below its size-band peers.

    423 of 1,251 indexed trials (33.8%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Breast Cancer trials is spread across many organizations.

    Memorial Sloan Kettering Cancer Center accounts for 98 of 1,251 trials (7.8%). 367 distinct sponsors appear on at least one study for this condition label.

  3. Typical Breast Cancer enrolment sits around 90 participants.

    Median target enrolment is 90 among the 1,225 trials that report a genuine target (sentinel values excluded). 630 of those (51.4%) plan for fewer than 100 participants.

  4. Breast Cancer research is mostly interventional.

    1,015 interventional and 236 observational studies make up this index (81.1% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 1235Phase 2256Phase 3100Phase 420

Open and recent trials

1,251 total, page 25 of 26

COMPLETED 9 participants

A Pilot Study of Bone Mineral Density in Postmenopausal Women After Treatment for Breast Cancer

University of Michigan Rogel Cancer Center

NCT00399321

COMPLETED Phase 1 9 participants

CP-724,714 in Treating Patients With Metastatic Breast Cancer

Jonsson Comprehensive Cancer Center

NCT00055926

COMPLETED Phase 1 9 participants

A Safety and Immunology Study of a Modified Vaccinia Vaccine for HER-2(+) Metastatic Breast Cancer

Bavarian Nordic

NCT00485277

COMPLETED NA 9 participants

Intraoperative Evaluation of Axillary Lymphatics

University of Wisconsin, Madison

NCT05094102

COMPLETED NA 8 participants

Assessing Response to Neoadjuvant Chemotherapy With HD PET/CT, Serum Glycomic Markers and Tissue Muc-1 Isoforms

University of California, Davis

NCT01110174

COMPLETED 8 participants

A Pilot Study of [Ga-68]PSMA PET/MRI for the Assessment of PSMA-positive Tumors

Case Comprehensive Cancer Center

NCT02978586

COMPLETED NA 7 participants

A Study of High-Dose Vit D Versus Standard of Care Vit D Supplementation

Wake Forest University Health Sciences

NCT05016310

COMPLETED 7 participants

Electronic Medical Record-Based Nudge to Reduce SLNB

University of Pittsburgh Medical Center

NCT06006910

COMPLETED NA 7 participants

Reducing Metabolic Syndrome Among Breast Cancer Survivors

Barbara Ann Karmanos Cancer Institute

NCT03719677

COMPLETED NA 7 participants

Engineering Gut Microbiome to Target Breast Cancer

Mayo Clinic

NCT03358511

COMPLETED Phase 1 7 participants

Visualization of the Effect of Acupuncture on Brain Serotonin in Breast Cancer Survivors

Abramson Cancer Center at Penn Medicine

NCT01018108

COMPLETED 7 participants

Pre-Surgical Qigong Therapy for Women With Breast Cancer

M.D. Anderson Cancer Center

NCT00495209

COMPLETED Phase 2 5 participants

Heated Chemotherapy for Cancers That Have Spread to the Chest Cavity

St. Luke's-Roosevelt Hospital Center

NCT01163552

COMPLETED NA 5 participants

A Study of Pre-Operative Treatment With Cryoablation and Immune Therapy in Early Stage Breast Cancer

Memorial Sloan Kettering Cancer Center

NCT02833233

COMPLETED 5 participants

Persistent Post-Surgical Pain in Women With BrCA

University of Florida

NCT02266082

COMPLETED Phase 2 5 participants

Interleukin-12 in Treating Patients With Metastatic or Recurrent Breast Cancer

Alliance for Clinical Trials in Oncology

NCT00004893

COMPLETED Phase 2 4 participants

Efficacy and Safety of BMS-690514 in Combination With Letrozole to Treat Metastatic Breast Cancer

Bristol-Myers Squibb

NCT01068704

COMPLETED Phase 1 4 participants

Koning Breast Computed Tomography Guided Biopsy

Koning Corporation

NCT01750320

COMPLETED NA 3 participants

Ipsilateral Peripheral Intravenous Access Procedures (The iPIVAP Study)

Duke University

NCT04570722

COMPLETED Phase 1 3 participants

Gene Therapy in Treating Women With Metastatic Breast Cancer

Max Sung

NCT00849459

COMPLETED NA 3 participants

Transcranial Direct Current Stimulation (tDCS) to Improve Fatigue and Cognitive Function

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT03487601

COMPLETED Phase 2 2 participants

Gefitinib With or Without Tamoxifen in Treating Patients With Tamoxifen-Resistant Metastatic Breast Cancer

Dartmouth-Hitchcock Medical Center

NCT00080743

COMPLETED 2 participants

Comparison Study of Breast Computed Tomography (CT) With Magnetic Resonance Imaging (MRI)

Emory University

NCT00957099

COMPLETED Phase 2 2 participants

Radiation Therapy After Lumpectomy in Treating Women With Ductal Carcinoma in Situ or Invasive Breast Cancer

Case Comprehensive Cancer Center

NCT00054301

COMPLETED 1 participants

Treatment AND Monitoring Patterns AND Clinical Outcomes IN Patients Receiving Palbociclib Combination Treatment (with AI OR Fulvestrant) FOR Hr+/her2- A/mbc IN A Community Oncology Setting.

Pfizer

NCT04498481

COMPLETED Phase 1 1 participants

Cellular Adoptive Immunotherapy in Treating a Patient Who Has Undergone a Donor Stem Cell Transplant for Breast Cancer That Has Spread to the Lung

National Cancer Institute (NCI)

NCT00301730

COMPLETED NA

Gabapentin For the Control of Hot Flashes in Women With Breast Cancer

Gary Morrow

NCT00022074

COMPLETED Phase 1

Vaccine Therapy Plus Sargramostim in Treating Patients With Stage III or Stage IV Cancer

University of Washington

NCT00005023

COMPLETED Phase 1

Liposomal Doxorubicin and Trastuzumab in Treating Women With Advanced Breast Cancer

NYU Langone Health

NCT00006825

COMPLETED Phase 2

Allogeneic Peripheral Stem Cell Transplantation in Treating Patients With Stage IV Breast Cancer

National Cancer Institute (NCI)

NCT00020176

COMPLETED Phase 2

Chemotherapy in Treating Women With Metastatic Breast Cancer

Daiichi Sankyo

NCT00004046

COMPLETED NA

Docetaxel Plus Garlic in Treating Patients With Locally Advanced or Metastatic Breast Cancer

National Cancer Institute (NCI)

NCT00079170

COMPLETED NA

Effect of Lifestyle Factors and Hormone Function on Breast Density in Healthy Hispanic Women Who Are Undergoing Mammography for Breast Cancer Screening

National Cancer Institute (NCI)

NCT00131950

COMPLETED Phase 2

BMS-247550 in Treating Women With Metastatic Breast Cancer

Memorial Sloan Kettering Cancer Center

NCT00020904

COMPLETED NA

Stress Reduction in Older Women With Stage II, Stage III, or Stage IV Breast Cancer

Unity Health Toronto

NCT00006346

COMPLETED Phase 1

Ravuconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Stem Cell Transplantation

National Institutes of Health Clinical Center (CC)

NCT00064311

COMPLETED Phase 3

Octreotide, Tamoxifen, and Chemotherapy in Treating Women With Breast Cancer

NSABP Foundation

NCT00002967

COMPLETED Phase 2

Erlotinib in Treating Patients With Locally Advanced or Metastatic Breast Cancer

National Cancer Institute (NCI)

NCT00030537

COMPLETED Phase 2

Raloxifene in Preventing Breast Cancer in Premenopausal Women

National Cancer Institute (NCI)

NCT00019500

COMPLETED Phase 1

Interleukin-12 in Treating Patients With Hematologic Cancers or Solid Tumors

Indiana University School of Medicine

NCT00003107

COMPLETED Phase 1

Docetaxel and Flavopiridol in Treating Patients With Locally Advanced or Metastatic Breast Cancer

National Cancer Institute (NCI)

NCT00020332

COMPLETED Phase 1

Radiolabeled Monoclonal Antibody Therapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Breast Cancer

Cancer Research Institute of Contra Costa

NCT00007891

COMPLETED Phase 3

Paclitaxel With or Without Gemcitabine in Treating Women With Advanced Breast Cancer

Eli Lilly and Company

NCT00006459

COMPLETED Phase 2

Tipifarnib Plus Tamoxifen in Treating Women With Metastatic Breast Cancer

National Cancer Institute (NCI)

NCT00052728

COMPLETED Phase 2

Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Women With Metastatic Breast Cancer

Hackensack Meridian Health

NCT00004906

COMPLETED Phase 1

HER-2 Protein Vaccine in Treating Women With Breast Cancer

Case Comprehensive Cancer Center

NCT00068614

COMPLETED Phase 1

Combination Chemotherapy With Suramin Plus Doxorubicin in Treating Patients With Advanced Solid Tumors

Mayo Clinic

NCT00003038

COMPLETED Phase 1

Radiation Therapy in Treating Women With Stage I or Stage II Breast Cancer

Radiation Therapy Oncology Group

NCT00002873

COMPLETED Phase 1

Tamoxifen Compared With LY353381 in Treating Women With Newly Diagnosed Breast Cancer

University of Kansas Medical Center

NCT00005886

COMPLETED Phase 3

Paclitaxel or Docetaxel in Treating Women With Advanced Breast Cancer

Aventis Pharmaceuticals

NCT00002662

← Previous Page 25 of 26 Next →

Phase Distribution

PhaseTrial count
Phase 1 235
Phase 2 256
Phase 3 100
Phase 4 20

Named interventions

Most-linked intervention names on Breast Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Fulvestrant Drug
33 trials
Paclitaxel Drug
32 trials
Trastuzumab Drug
26 trials
Letrozole Drug
24 trials
Pembrolizumab Drug
23 trials
Cyclophosphamide Drug
21 trials
Capecitabine Drug
20 trials
Abemaciclib Drug
19 trials

US sites by state

Facility locations filed on Breast Cancer trials. A trial with sites in several states counts in each.

California 298 trials
New York 270 trials
Texas 210 trials
Florida 206 trials
Massachusetts 184 trials
North Carolina 126 trials
Illinois 123 trials
Pennsylvania 122 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Breast Cancer page

1,251 registered trials, 423 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Breast Cancer condition card totals 1,251 registered trials; most-linked intervention Fulvestrant; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.